4D Molecular Therapeutics(FDMT)
Focus: 4D Molecular Therapeutics is a publicly traded gene therapy company focused on treating rare and serious diseases including retinal disorders, cystic fibrosis, and Fabry disease through innovative viral vector approaches. The company operates as a clinical-stage biotech with a diversified pipeline across multiple therapeutic areas.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
14+3 this month
Stable — net +3 jobs in 30d
7 added, 4 removed. Backfill posture.
Should You Work at 4D Molecular Therapeutics?
AI assessmentStrong scientific opportunity in gene therapy with near-term Phase 3 catalyst, but join with clear-eyed awareness of significant cash burn, modest headcount, and mixed leadership signals.
Why Work Here
- Lead a cutting-edge gene therapy platform with 6 active programs spanning Phase 1–3, including Phase 3 program 4D-150 for neovascular AMD poised for near-term readouts.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Pipeline & Clinical Trials
Observation
ChoroideremiaClinical Trials (2)
NCT045171494D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
Phase 1/2Help build intelligence for 4D Molecular Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.